Vision in the mesopic range is affected by a number of inherited and acquired clinical disorders. Here we review these conditions and summarize the historical background, describe the clinical characteristics alongside the genetic basis and molecular biological mechanisms giving rise to rod and cone dysfunction relevant to twilight vision. The current diagnostic gold standards for each disease are discussed and curative and symptomatic treatment strategies are summarized.
Introduction
The visual system allows us to see over a remarkable range of illumination.
In fact, the visual system covers about 11 log 10 units change in illumination (Stockman and Sharpe this issue). We can adapt to see in bright sun light relying purely on the cone system as well as in near complete darkness by switching to the more sensitive rod system. The transition from photopic (light) to scotopic (dark) vision is part of what is known as dark-adaptation.
Mesopic vision refers to visual function at certain light levels (twilight) at which both the cone-and rod-system are active. Mesopic vision covers about 32 to 0,0032 Candela per centimeter square (cd/m 2 ). It is important to remember that dark adaptation may take up to 40 minutes achieve full sensitivity. Mesopic vision depends on both the external light level and the speed of the biochemical processes providing the energy to turn the rodsystem fully on. Problems in mesopic vision are related to a pathological transition from photopic to scotopic vision and may present clinically as night blindness. The importance of rod function in mesopic conditions is exemplified by the fact that the contrast sensitivity of the rod system is highest at light levels where cones are also still contributing to vision.
The term "night blindness" was introduced by Brodley and, though not strictly accurate, is now in common use (Bordley, 1908) . Alternative used terms include "nyctalopia" (seeing at night, preferred in the French literature) or "hemeralopia" (seeing in the day). Strictly speaking nyctalopia means day blindness, e.g. in cone monochromacy. There is much controversy around the correct use for these terms with the Anglo-Saxon literature directly opposing the French literature (Duke-Elder, 1963; Skinner, 1970; Brouzas et al., 2001) . In this review we refer to "impaired night vi-sion" when we use the term "night blindness".
In developed societies photopic conditions extend beyond the daylight hours. That is to say many of us will rarely employ scotopic vision and paracentral vision in the mesopic range is only needed under certain circumstances. One of the most important situations in which most of us still rely on mesopic vision (rods and cones are active) is driving. There are however certain work environments, leisure and sport activities were peripheral vision and hence rod signals are important, even at high levels of scene luminance e.g., 10 cd/m 2 .
Vision in the mesopic range can be impaired in a number of diseases, some of which are inherited and others are acquired. Here we review these disorders and try to differentiate how they may affect mesopic vision rather than pure rod (scotopic) vision. Additionally, we discuss how cone dysfunction may also impair the early transition from photopic to mesopic vision. Finally we propose a short guideline for investigating these patients including the cardinal clinical features and history, the relevant investigations and treatment options.
Reduced vision in the mesopic range due to rod dysfunction
Here we review the human conditions in which rod dysfunction leads to slow dark adaptation and consequently to impaired vision in the mesopic range. It is worth remembering that although the biochemical processes driving rod function may be slowed due to defective enzymes, in many instances the cellular metabolism permits adaptation such that normal rod function may be observed after prolonged periods of dark adaption.
Hereditary conditions
A genetic mutation affecting any single protein or enzyme involved in the retinoid processing cycle potentially causes retinal disease (reviewed by Lamb and Pugh (Lamb and Pugh EN, 2004) ). The five diseases relevant to the present review are retinitis pigmentosa, retinitis pigmentata alibscens, Bothnia dystrophy (BD), fundus albipunctatus, Congenital stationary night blindness and Oguchi disease.
Retinitis pigmentosa comprises the largest group and three genetically distinct variants, retinitis punctata albescens, Bothnia dystrophy, and Newfoundland rod-cone dystrophy will be discussed separately.
Retinitis pigmentosa (RP)
Retinitis pigmentosa (RP), a clinically and genetically heterogeneous group of disorders, is the most common hereditary cause for visual impairment in all age groups. It has a prevalence of approximately 1:3500 (Pagon, 1988; Phelan and Bok, 2000) .
The classical symptoms of night blindness at early age and bilateral peripheral VF loss are predominantly observed in patients with rod-cone RP. Although macular vision is relatively preserved, cone degeneration in the later phases of the disease will affect central VA and day vision.
Progression to legal blindness may happen as early as in the third or as late as in the sixth decade (Berson, 1996) . Complete blindness occurs in a proportion of RP patients. It is not possible to predict speed and extent of visual failure.
Patients who present with loss of central vision, night blindness and VF loss are likely to suffer from cone-rod dystrophy/degeneration, a RP allied disease (Phelan and Bok, 2000) .
The age of onset of symptoms is related to the mode of inheritance with children being more likely to suffer from X-linked RP, whilst younger to older adults are more likely to suffer from autosomal recessive or autosomal dominant RP, respectively (Weleber, 1994) . The increasing number of RP genes (Hims et al., 2003; Delyfer et al., 2004 ) is regularly updated on RetNet (www.sph.uth.tmc.edu/Retnet). The classification of these genes into functional classes is complex. Phelan and Bok classified these into 7 main functional groups (1) the visual cascade, (2) the visual cycle, (3) tetraspanins, (4) photoreceptor cell transcription factors, (5) catabolic functions in the retina, (6) mitochondrial genes and (7) genes of yet unknown function (for review see (Phelan and Bok, 2000) and references therein).
Kalloniatis and Fletcher recently reviewed the underlying biological mechanisms (Kalloniatis and Fletcher, 2004) .
Fundus examination shows the typical picture of a mottled or granular appearance of the retina early in the disease (Figure 1 ) which develops into bone-spicule pigmentary deposits overlying the depigmented retina ( Figure 2 ) (Phelan and Bok, 2000) . There is some variation in the appearance of pigmentary changes and window-like holes through the RPE are observed as are hypopigmentation, translucence and accumulation of pigment deposits of circular shape. Retinal atrophy results in attenuation of the retinal blood vessels and a pale disc due to loss of the nerve fibre layer (Phelan and Bok, 2000; Weleber, 1994; Heckenlively, 1988) .
Electroretinography plays a central role in the diagnosis of RP (see (Heckenlively, 1988; Marmor and Zrenner, 1998-99) and references therein).
In the classical picture of rod degeneration abnormalities in the scotopic ERG precede those in the photopic ERG. In contrast in RP allied diseases presenting with cone-rod dystrophy the photopic ERG becomes abnormal first (Phelan and Bok, 2000) . Occasionally a disproportional disruption of (Spalton et al., 2005) ). (Spalton et al., 2005) (Weiss, 1991) ). Genetic counselling poses a particular challenge (Gross-Jendroska et al., 1992) . Dietary supplementation with vitamin A at a daily dose of 15,000 IU (international units) may slow the progression of RP in the early stages of the disease (Berson et al., 1993) .
Patients should avoid taking vitamin E supplements, because this may hasten the disease, possibly by reducing the amount of vitamin A reaching the eye (Berson, 1996) . There are a number of controversial treatment strategies not reviewed here (see (Kalloniatis and Fletcher, 2004; Delyfer et al., 2004) and references therein). There is experimental evidence an-imals that genetherapy and specifically gene replacement therapy, may be an exciting avenue to be pursued (for review see (Rolling, 2004) and references therein).
Retinitis punctata albescens (RPA) Retinitis punctata albescens (RPA)
is a rare progressive, autosomal recessive disorder caused by a number of different mutations in a number of genes Burstedt et al., 2005 Burstedt et al., , 2003 Granse et al., 2001; Burstedt et al., 2001 Burstedt et al., , 1999 Weiss et al., 1992; Morimura et al., 1999; Fishman et al., 2004) . The affected genes are the Retinaldehyde-Binding Protein 1 (RLBP1) gene, the peripherin/RDS gene, the rhodopsin gene. The Arg135Trp point mutation in the rhodopsin gene was discovered by Souied in 1996 (Souied et al., 1996 and the RLBP1 mutation was first described by Maw in 1997 (Maw et al., 1997) .
Patients usually present in early childhood with night blindness Morimura et al., 1999) . As the disease progresses visual acuity decreases and visual fields become restricted.
The examination of the fundus demonstrates whitish spots throughout the fundus (Figure 3 ), sometimes with a annulus appearance round the macula Morimura et al., 1999) . With loss of the nerve fibre layer the retinal vasculature becomes more attenuated (Morimura et al., 1999) .
Fluorescein angiogram may show granular hyperfluorescence of the retina and window defects over the macula .
Optical coherence tomography (OCT) has been used to demonstrate thinning of the retina around the macula, mainly affecting the outer nuclear layer . (Spalton et al., 2005) ).
The ERG is severely abnormal, if not unrecordable for all modalities (photopic, scotopic and mesopic) Morimura et al., 1999) . Scotopic blue seems to be particularly vulnerable (Morimura et al., 1999) .
The differential diagnosis includes RP and Nakamura and colleagues make the point that although the examination of the fundus shows distinctive subretinal flecks in FA, additional genetic analysis may be required .
Bothnia dystrophy (BD) Bothnia dystrophy (BD) represents a subgroup
of RPA patients with less severe disease due (Burstedt et al., 1999 (Burstedt et al., , 2001 ).
These patients are homozygous for the RLBP1 mutation Arg234Trp and were from northern Sweden. They have a predilection to exhibit an atrophicappearing macular lesion, particularly when over the age of 30.
There is no specific treatment.
Newfoundland rod-cone dystrophy (NFRCD) Newfoundland rod-cone dystrophy (NFRCD) represents another subgroup of RP patients with a particular phenotype due to a mutation in the RLBP1 gene (Eichers et al., 2002) . The onset of the disease is early (< 10 years of age) and rapidly progresses so that legal blindness is usually reached between the age of 40-50 years. Night blindness is the earliest symptom, followed by progressive loss of peripheral, central and colour vision.
The fundus appearance is somehow distinct to what is observed in RP or BD. In contrast to RP, there are usually no bone spicule pigmentations until late in the disease. In contrast to BD the macular appears normal or shows a "beaten-bronze" atrophy (Eichers et al., 2002) . The observed white stippling of the retina and annulus around the macula is similar to what is observed in RPA.
The rod ERG is affected early in the disease, followed by an abnormal cone ERG (Eichers et al., 2002) .
Congenital stationary night blindness (CSNB) Congenital stationary
night blindness (CSNB) is an umbrella term for a heterogeneous, nonprogressive group of disorders presenting in childhood with night blindness and occasionally other ocular symptoms such as nystagmus, decreased visual acuity, myopia and hyperopia (Zeitz et al., 2005; Abramowicz et al., 2005; Weleber, 2002; Wutz et al., 2002; Lorenz et al., 1996) . The autosomal dominant variant of CSNB was first described in the Nougaret family by the Belgian ophthalmologist Florent Cunier (Cunier, 1838; JP, 2001) in collaboration with a local antiquarian (M Chauvet) from a small village near to Montpelier. The founder of this family was a French butcher by the name of Jean Nougaret born in Provence in 1636. The Nougaret family was followed up by Nettleship (Nettleship, 1907) . Whilst many genes are described the underlying biochemical features
are not yet unraveled and more functional studies are needed (Muradov et al., 2003; Mansergh et al., 2005) . There is a recent report of benign familial myoclonic epilepsy in 3 patients with CSNB suggesting that some of these patients may suffer from a channelopathy (Manabe et al., 2002) which is consistent with the findings in a new animal model (Mansergh et al., 2005) .
The fundus may appear normal, and this variant is referred to as the Schubert-Bornschein variant (Schubert and Bornschein, 1952) .
The ERG responses in X-linked and autosomal recessive CSNB show a selective reduction of the b-wave, whilst the a-wave is almost completely normal, giving rise to the typical picture of the a-wave being larger than the b-wave (Miyake et al., 1986 (Miyake et al., , 1994 Bradshaw et al., 2004; Langrova et al., 2002) , a so-called "negative" ERG. Differences in the rod and cone b-wave responses permit to distinguish CSNB1 from CSNB2 (Zeitz et al., 2005) . The ERG allows for further sub classification of the SchubertBornschein variant dependent on whether the defect of the bipolar cells is complete or incomplete (Schubert and Bornschein, 1952; Miyake et al., 1986 ).
The discovery of new phenotypes makes the interpretation of the ERG more complex and there is no clear genotype phenotype correlation (Kabanarou et al., 2004; Allen et al., 2003) .
Fundus albipunctatus Fundus albipunctatus (FA), first described by Lauber in 1910 (Lauber, 1910) presents with non-progressive, or very slowly progressive night-blindness without associated retinal dystrophy. The typical clinical findings are multiple whitish yellow spots in the fundus which tend to be scattered as an annulus around the macular (Figure 4) . FA can present with and without macular atrophy (Nakamura et al., 2003) .
FA is caused by a number of distinct mutations in the RDH5 gene which encodes for the 11-cis retinol dehydrogenase of the retinal pigment epithelium (Nakamura et al., 2003; . The biological function of this enzyme is to oxidises the alcohol 11-cis retinol to the aldehyde 11-cis retinal. Impairment of this process results in reduced retinol delivery and prolonged dark-adaptation.
The interesting finding is that patients suffer from severely depressed (Spalton et al., 2005) ).
rod-function in the early stages of dark adaptation. However, rod function starts to improve within about 30 minutes of adaptation and returns to near normal levels after 2-3 hours of adaptation. (Carr et al., 1974) . The biochemical basis for this phenomenon is delayed regeneration of rod visual pigment. It is of note that this also delays the regeneration of cone visual pigments. In fact cone dysfunction can be demonstrated in about 38% of patients with FA Niwa et al., 2005) . Macular lesions are not required for reduced cone function.
There is no specific therapy for fundus albipunctatus.
Oguchi disease Oguchi disease is a non-progressive disorder first described by Oguchi in 1912 (Oguchi, 1912 in which dark adaptation is 8 to 10-times slower than normal (Carr and Ripps, 1967; Sharp et al., 1990; Cideciyan et al., 1998) . Mizuo (Mizuo, 1913) observed in these patients by examination of the fundus that under light adapted conditions the retina had a metallic, phosphorescence-like sheen which disappears with prolonged dark adaptation, a phenomenon which had since carried his name. Interestingly pigment regeneration appears to be normal despite a severely reduced dark adaptation (Lamb and Pugh EN, 2004 ). Oguchi disease is caused by mutations in genes encoding either of two proteins, RR or Arr (reviewed in (Dryja, 2000) ). These mutations are more common in the Japanese compared to the European population.
Standard full field scotopic ERG shows absent rod responses and a reduced a-wave. The cone and flicker ERG is normal. The photopic ERG permits differentiation of patients with Oguchi disease from complete CSNB where the ON response is reduced (Miyake et al., 1996) .
Acquired conditions
Vitamin A deficiency (VAD) Vitamin A deficiency (VAD), defined by serum retinol concentration <0.7 µmol/L is world wide the most common cause for xeropthalmia (xeros, dry, ophthalmia, inflamed eye) which is followed by night blindness (Tielsch and Sommer, 1984) . Although recognized since the early Egyptian times (Wolf, 1978) , the typical fundus appearance was not described until 1928 by Uyemura (Uyemura, 1928) . Fuchs subsequently proposed the name the disease Uyemura syndrome (Fuchs, 1928; Fuch, 1959) .
VAD is a public health issue in countries with part of the population faces nutritional problems. VAD has recently been described in Afghanistan (Nabakwe et al., 2005) , Kiribatie (Schaumberg et al., 1996) , Malaysia (Ngah et al., 2002) , Mali (Schemann et al., 2002; Farbos et al., 2000) , the Marshall Islands (Maqsood et al., 2004) , Myanmar (Singh and West KP, 2004) , Nepal (Taren et al., 2004; Singh and West KP, 2004) , Niger (Blum et al., 2004) , Nigeria (Oso et al., 2003) , Philippines (Rosen et al., 1994) , Sri Lanka (Singh and West KP, 2004; Brink et al., 1979) , Tanzania (Wedner et al., 2000) , Thailand (Singh and West KP, 2004; Bloem et al., 1989) , Yemen (Rosen et al., 1996) , Zaire (Donnen et al., 1996) , Java (Bergen HR et al., 1988) , Malawi (Tielsch et al., 1986) . Xerophthalmia re-mains the leading cause of acquired pediatric blindness. The WHO estimates that about 140-250 million world wide are at risk of a vitamin A deficiency disorder (Underwood, 2004) .
The earliest symptom of VAD is night blindness, followed by peripheral The differential diagnosis for VAD is wide and apart from patients suffering from malnutrition in the mentioned areas (Mihora et al., 2004; de Pee et al., 2003; Singh and West KP, 2004; Ahmed et al., 2000; Ahmed, 1999; Singh and West KP, 2004; Saunders et al., 2004; Ramalho et al., 2002; Semba et al., 2003; Christian, 2002; Resnikoff et al., 1992; Asrat et al., 2002; Haidar and Demissie, 1999; Shaw et al., 2005; Singh and West KP, 2004; Christian, 2002; de Pee et al., 2003; Singh and West KP, 2004; Mele et al., 1991; Al-Kubaisy et al., 2002; Nabakwe et al., 2005; Schaumberg et al., 1996; Ngah et al., 2002; Schemann et al., 2002; Farbos et al., 2000; Maqsood et al., 2004; Singh and West KP, 2004; Taren et al., 2004; Singh and West KP, 2004; Blum et al., 2004; Oso et al., 2003; Rosen et al., 1994; Singh and West KP, 2004; Brink et al., 1979; Wedner et al., 2000; Singh and West KP, 2004; Bloem et al., 1989; Rosen et al., 1996; Donnen et al., 1996; Bergen HR et al., 1988; Tielsch et al., 1986) Rosen et al., 1996; Donnen et al., 1996; Bergen HR et al., 1988; Tielsch et al., 1986 ).
The fundus is normal in early VAD, but may later on show multiple white or grey-white spots in the peripheral retina (Uyemura, 1928) , which usually disappear with vitamin A supplementation (McBain et al., 2005; Apushkin and Fishman, 2005 ).
The ERG response shows elevated thresholds for both rods and cones, with the rods being more severely affected (Perlman et al., 1983) . In severe cases the rod ERG can be undetectable. The ERG generally normalizes with treatment. McBain and colleagues describe an interesting patient who reported she would see "white as green" and had a selective loss of the S-cone function (McBain et al., 2005) . One of the two cases reported by
Bennett and colleagues was a photographer by profession and reported that colours appeared as if seen through a yellow filter, the other patient reported that colour appeared as if seen through a red screen (Bennett et al., 2004) .
Fluorescein angiography suggests that the white areas in the fundus represent loss of pigment from the retinal pigment epithelium (Sommer, 1982) .
The treatment of VAD is straightforward by supplementing vitamin A.
An interesting new approach using genetically modified rice and maize may may eventually contribute enriching vitamin A in the food, but logistic problems and controversial economical issues need to be addressed (Editorial, 2005) . VAD and xeropthalmia were already known to the ancient Egyptians and Greeks who treated it with calf's or goat's liver which have a high vitamin A content (Wolf, 1978) (for a historical review see reference (Wolf, 1996) ). However and sadly it needs to be remembered that most of the children affected by VAD will receive treatment too late to make a full recovery.
Melanoma associated retinopathy (MAR) Melanoma associated retinopathy (MAR) belongs to the paraneoplastic syndromes and is characterized
by the combination of night blindness, phosophenes (the subjective appearance of flickering lights), colour deficits on the tritan axis, reduced visual acuity and central visual field loss occurring in patients with metastatic cutaneous melanoma (Sawyer et al., 1976; Weinstein et al., 1994; Kellner et al., 1995; Jacobson, 1998; Petzold and Plant, 2005; Pfohler et al., 2003; Gass, 1984) . Visual symptoms frequently start with night blindness and shimmering, flickering, or pulsating photopsias followed by progressive loss of visual acuity (Keltner et al., 2001) . The occurrance of photopsias is very sudden and indicative of loss of vision.
Sawyer was probably the first to recognize in 1976 the relationship between a non-ocular cancer and retinal pathology (Sawyer et al., 1976 ).
Ripps and colleagues were the first to describe the occurrence of night blindness and photopsias in a 30-year old man with melanoma, but they suggested that toxic properties of the chosen chemotherapy (vincristine)
were causative (Ripps et al., 1984) . Generally Gass is accredited for truly recognizing the MAR syndrome (Gass, 1984) .
The mostly accepted pathophysiological mechanism is that (perhaps in an attempt to limit tumour growth) the human immune-system produces antibodies which cross-react with bipolar cells of the retina (Milam et al., 1993; Kellner et al., 1995; Klopfer et al., 1997; Boeck et al., 1997; Weinstein et al., 1994) , although this could not be shown in all cases (Fishman et al., 1996; Bret-Dibat et al., 1996; Rougier et al., 1995) and crossreactivity with other retinal cells is also observed (Keltner et al., 2001) .
One group provided some experimental evidence that the transfer of human IgG from MAR patients into the vitreous of the monkey induces ERG changes also seen in MAR (Lei et al., 2000) .
The fundus has been reported as normal in 19 (44%) of 43 patients. In some cases a pale optic disc, attenuation of retinal vessels including retinal periphlebitis, changes of pigmentation, occasional vitreous cells (see Table   6 in reference (Keltner et al., 2001) ). The inflammatory changes may be more widespread, involving larger parts of the posterior uvea.
Nyctometry (see Assessment, below) is abnormal in MAR patients (Pfohler et al., 2003) . Psychophysical tests suggest a specific M-cell dysfunction with preservation of P-cell function (Arden et al., 1995) .
The ERG typically shows a markedly reduced b-wave due to the defunct bipolar cells. A normal A-wave indicates normal functioning of the photoreceptors (Fishman et al., 1996; Barnes et al., 2002) . The ERG pattern resembled the one found in CSNB patients in 54 of 56 patients recently reviewed by Keltner and colleagues (see Table 7 in reference (Keltner et al., 2001) ).
Treatment of the underlying melanoma is the primary concern to the physician. With regard to the MAR syndrome there are anecdotal reports that corticosteroids, plasmapheresis, intravenous immunoglobulins (IVIg), azathioprine, gabapentin, radiation and cytoreductive surgery may be of some benefit (Guy and Aptsiauri, 1999; Keltner et al., 2001 ).
Cancer associated retinopathy (CAR) Cancer associated retinopathy
(CAR) is another cancer associated paraneoplastic retinal degeneration (Sawyer et al., 1976) . CAR can be seen with tumors such as pulmonary small cell carcinoma, breast and other gynecological cancers, endocrine and other malignancies (Keltner et al., 2001 ).
The main symptoms are loss of visual acuity associated with photopsias which can precede the detection of the cancer by many months. Rod dysfunction is the cause for night blindness, prolonged dark adaptation, peripheral and ring scotomata. Cone dysfunction results in photosensitivity, decreased colour vision and visual acuity and central scotomata (Keltner et al., 2001; Petzold and Plant, 2005) .
Over 15 different types of antibodies are described with the 23-KDa protein recoverin being the most commonly found antigen, followed by the 46-KDa protein α-enolase and others (i.e. neurofilaments, heat shock protein 70, TULP1, etc.) (Keltner and Thirkill, 1998; Adamus et al., 2004; Polans et al., 1995; Thirkill et al., 1992) .
The ERG can be abnormal either for cone-or rod-function or for both presumably dependent upon the proteins targeted by the antibodies.
Treatment of the underlying cancer is the main problem.
Autoimmune-related retinopathy and optic neuropathy (ARRON) syn-
drome Autoimmune-related retinopathy and optic neuropathy (ARRON) syndrome represents a rare and heterogeneous group of patients with retinal degeneration and optic neuropathy thought to be associated to autoimmune antibodies without evidence of cancer, but rather to a systemic autoimmune disease (Keltner et al., 2001) . The symptoms frequently resemble those observed in CAR patients. Indeed, antibodies against similar antigens (i.e. recoverin) are found in ARRON and CAR (Keltner et al., 2001; Adamus et al., 2004) .
The ERG resembles that seen in CAR patients.
No specific treatment is known and various immunosuppresive strategies have been tried.
Reduced vision in the mesopic range related to cone dysfunction
The relevance of cone disease The human retina comprised three types of cones which in their absorption spectra. The S-cones are most sensitive in the short wavelength spectra, the M-cones in the middle wavelength spectra and the L-cones in the long wavelength spectra.
Cone disease may cause problems on first entering dark.
Enhanced S-cone syndrome (ESCS) Enhanced S-cone syndrome (ESCS)
is a progressive autosomal receptive disorder which can be caused by a large number of mutations in the NR2ER gene (synonymous to PNR) (Haider et al., 2000) (for review of these mutations see references Wright et al., 2004) ). Marmor et al. coined the term ESCS (Marmor et al., 1990) . Inherited retinal dystrophies generally affect the rods and all three cone types (S-cone, M-cones and S-cones). Enhanced S-cone syndrome (ESCS) represents a rare exception because only M-and L-cones are affected, whilst the S-cones or blue cones exist in excess (Peng et al., 2005) . It has been suggested that NR2ER may be important during retinal development (Bumsted O'Brien et al., 2004; Milam et al., 2002) .
Patients with ESCS suffer from night blindness due to rod dysfunction.
Most young patients suffer from bilaterally reduced visual acuity (VA) to less than 0.8, which decreases further with age so that by the age of 20 VA generally decreased to less than 0.4 (Nakamura et al., 2004; Sharon et al., 2003; Yamamoto et al., 1999; Usui et al., 2004) . The peripheral VF is reduced and ring scotomata can be observed . Colour vision may or may not be impaired depen-dent on severity. The severity and prognosis of ESCS varies from very mild to severe (Nakamura et al., 2004) , dependent on the underlying mutation.
The pathognomic finding in ESCS is the ERG demonstrating "hyperfunction 1 " of S-cones (Marmor et al., 1990 (Marmor et al., , 2004 (Marmor et al., , 1999 Hood et al., 1995) .
The diagnosis of ESCS is frequently based on the typical findings in the spectral ERG which combines hypersensitivity to blue stimuli with a hyposensitivity to red stimuli Marmor et al., 1990) . In most patient there is no recordable rod function on ERG, but in very mild form of ESCS the rod ERG showed low rod b-waves .
The fundus findings include cystoid changes in the macula and may also show degenerative changes in the vascular arcade to the mid peripheral retina. Pigmented spots in degenerating areas can also be seen Jurklies et al., 2001; Marmor et al., 1990) .
Optical coherence tomography (OCT) may show large macular retinoschisis and an abnormal laminar retinal architecture .
Fluorescein (midphase) may reveal hyperfluorescence of the degenerative regions and temporal hypofluorescence in areas where pigmented spots are seen by direct examination of the fundus .
The differential diagnosis of mutations to the NR2E3 gene includes Goldmann-Favre syndrome (Sharon et al., 2003) , autosomal recessive retinitis pigmentosa (Gerber et al., 2000) , and clumped pigmentary retinal degeneration (Sharon et al., 2003) .
Sorsby fundus dystrophy (SFD) Sorsby fundus dystrophy (SFD) rep-
resents a rare autosomal dominant macular degeneration, first described by Sorsby and Marson in 1949 (Sorsby and Mason, 1949) , which presents with bilateral loss of central vision in the adult. Some patients may present with nyctalopia prior to the development of the maculopathy (Capon et al., 1988; Polkinghorne et al., 1989) . Pigment dispersion glaucoma is also observed.
SFD is caused by a mutation on chromosome 22q12-q13 resulting in decreased activity of TIMP3, the inhibitor to the metaloproteinase 3 (MMP3) (Weber et al., 1994) . The condition is progressive (Weber et al., 1994) .
TIMP3 and MMP3 participate in a complex network of enzymes needed for the normal remodeling of the extracellular matrix (ECM) (Bergers and Coussens, 2000) . The degrading activity of MMPs is high and MMPs are tightly controlled by their specific tissue inhibitors (TIMP). A range of disorders has been related to MMPs, but of the TIMPs only TIMP3 has so far been related to disease (Klenotic et al., 2004) . In SFD Ser-Cys mutants of TIMP3 accumulate in drusen and in Bruch's membrane similar to what is seen in the more common age-related macular degeneration (AMD) (Tabata et al., 1998; Weber et al., 1994; Kamei and Hollyfield, 1999) . The mechanism leading to TIMP3 accumulation remains unknown but is likely to be related to impaired degradation of the protein (Chong et al., 2003) .
Fundus examination in the earlier stages show juxtafoveal choroidal neovascularization (Barbazetto et al., 2005) , diffuse fine yellowish-white deposits. Retinal hemorrhages may be present (Ayyagari et al., 2000) .
Later the picture is dominated by retinal and macular atrophy ( Figure 5 ) (Atan et al., 2004) . Fluorescein angiography shows the classical features (Spalton et al., 2005) ).
of choroidal neovascularization, that is to say delayed choroidal filling and retinal pigment epithelial mottling (Barbazetto et al., 2005; Atan et al., 2004) .
There is no specific treatment, but retinal neovascularisation may be limited by photodynamic therapy or steroids (Peiretti et al., 2005; Atan et al., 2004) . On a very short term basis vitamin A supplement may improve the symptoms (Berson, 2000) .
The differential diagnosis includes other conditions with early onset retinal and macular degeneration.
Assessment
The most important, easiest and most economical approach is to ask the patient if he/she experiences any problems with his/her night vision.
Patients who drive may be particularly aware of impaired vision in the mesopic range. Accurate and reproducible quantification of mesopic vision and changes in mesopic vision over time are very difficult. Discussion of the complexities of mesopic photometry is beyond the scope of this review and the interested reader is referred to the paper by Stockman and Sharpe in this issue. Here we restrict the discussion to some pragmatic assessments which are relevant for assessment of night driving abilities in some countries.
Historically the Nyktometer (Rodenstock) was the probably the most frequently used instrument for assessment of visual acuity under mesopic conditions (Hartmann and Wehmeyer, 1980; Kolling and Schratz, 1991; Schlag, 1993) . Several developments have been made and the Mesotest II (Oculus), the Kontrastometer (BKG Medizin Technik GmbH) and the nyktometer 500 (Rodenstock) may currently be the most frequently used aparati (Puell et al., 2004; Schlote et al., 1997; Kolling and Schratz, 1991;  , DOG).
The Nyktometer 500 allows for the assessment of monocular and binocular visual acuity under mesopic conditions using Landolt rings (recommended is the use of plate 505). The forehead is rested against a flexible, soft plastic cover which shields the eyes from any stray light. It is possible to keep the spectables on during the test. The aparatus allows to correct for night myopia by adding minus lenses.
The Mesotest II is very similar to the Nyktometer. One additional fea-ture is that the rear wall of the aparatus can be removed allowing for vision through a half permeable mirror. The idea is that this may allows to avoid night myopia. If this option is used care needs to be taken that the aparatus points towards a non-light reflecting wall and that the illumination in the room is kept constant.
The Kontrastometer again is very similar to the Nyktometer. An advantage of this aparatus is that visual acuity is tested using Landolt rings which are illuminated from behind and also from the side allowing for variation of contrast which is of use for those patients who suffer from very poor mesopic vision. Additionally the Landolt rings can be turned so that the patient cannot memorise the opening position of the ring. The core features of these three aparati are summarized in Table 1 . Other tests include the Pelli-Robson letter contrast sensitivity (Wood and Owens, 2005) , contrast letters (Pesudovs et al., 2004; Smith RA, 1973) and a new automated test developed by Chisholm and Barbur (Chisholm et al., 2003) .
The relationship between mesopic vision and dark-adaptation is of particular importance for divers, pilots, etc. and a number of tests assess this function (Plainis et al., 2005; Babizhayev, 2003; Reiner, 1997) . Other visual functions affected by reduced vision in the mesopic range are motion (Takeuchi et al., 2001 ) and distance judgment (Bourdy et al., 1991) .
Electroretinography (ERG)
Electroretinography has a central role in the diagnosis of all diseases described in the review. It permits testing of rod function during dark adaptation by providing a white flash of light (scotopic ERG), cone function adapted to specific light levels (photopic ERG) and both rods and cones if a sufficiently bright light flash is given under dark adaptation (mesopic ERG). At intermediate light levels cone function can be isolated by recording the ERG to rapid flicker or a long wave length stimulus as the rods will not respond to either of these.
The ERG recordings show an initial negative deflection (downwards on the y-axis) due to closure of cation channels in the outer segment membrane. This is followed by a positive deflection (upwards on the y-axis) due to activity of the photoreceptors and retinal neurons. In this review we frequently refer to the ERG b-wave which reflects the transmission of the signal from the photoreceptors to the second-order neurons.
In diseases with predominant or early degeneration of rods, pathological changes in the scotopic ERG precede those of the photopic ERG. Vice versa diseases affecting predominantly the cones mainly change the appearance of the photopic ERG. In cone-rod dystrophy the photopic ERG is affected first, but the scotopic ERG is usually pathological as well. It needs to be remembered that the standard ERG is not sensitive enough to detect diseases limited to the macula with a limited amount of cone loss.
Conclusions
Impaired vision in the mesopic range is probably the most sensitive and earliest sign of a range of diseases. Frequently taking a history and asking for problems with night vision is sufficient to identify affected patients. Simple tests for assessing mesopic vision have been established and have been recommended as screening tests particularly for VAD which remains the most frequent cause for acquired blindness. More detailed tests of mesopic vision including the nyctometer, ERG, contrast sensitivity, the psychophysics of the dark adaptation and others contribute unraveling the function of the visual pathways and their genetic and molecular biological basis.
It is important to remember that disorders of both the rod and cone systems can affect vision at mesopic levels. However, relatively little is known about how the interactions between the two systems, which only occur at mesopic light levels, can be modified in disease and how this may be manifested in the symptomatology. Even less is known about optic nerve and cerebral disease as in those disorders visual function is almost exclusively studied under photopic conditions. And yet patients with optic nerve disease, for example, will often report that they see better in bright than dim light or vica versa. Patients with bilateral occipital dysfunction may report that their visual world appears abnormally dark, and that "if only there were more light" they would be able to see.
The other articles in this issue, and a growing scientific literature, are evidence of increasing realisation that mesopic vision is also important in everyday life of patients, particularly where driving at night is concerned. In this review we have attempted to provide an understanding of the range of rod and cone system disorders which may result in impaired vision in the mesopic range. In the coming years a greater understanding of the consequences of these and other disorders for mesopic vision will emerge.
